title: A myriad of pathways to NASH.
abstract: Nonalcoholic steatohepatitis (NASH) is defined histopathologically by the presence of macrovesicular steatosis, cellular ballooning, and inflammation. NASH represents a complex multifactorial disease that typically occurs within the context of the metabolic syndrome. NASH lacks homogeneity, and other forms of NASH can present atypically. Less than 50% of patients with NASH respond to pharmacologic treatment, which speaks to this heterogeneity. The authors discuss drugs, disease entities, and nutritional states that can cause or exacerbate underlying NASH indirectly through worsening insulin resistance or directly by interfering with lipid metabolism, promoting oxidative injury, or activating inflammatory pathways.
authors: Division of Gastroenterology & Hepatology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
authors: Soledad
authors: S
authors: Larrain
authors: Mary E
authors: ME
authors: Rinella
mesh_terms: D000638:Amiodarone / Q000009:adverse effects; D044966:Anti-Retroviral Agents / Q000009:adverse effects; D001424:Bacterial Infections / Q000150:complications; D002188:Cannabis / Q000009:adverse effects; D004032:Diet / Q000009:adverse effects; D005234:Fatty Liver / Q000139:chemically induced / Q000188:drug therapy / Q000235:genetics; D030342:Genetic Diseases, Inborn / Q000150:complications; D005938:Glucocorticoids / Q000009:adverse effects; D006801:Humans; D007037:Hypothyroidism / Q000150:complications; D007333:Insulin Resistance; D007410:Intestinal Diseases / Q000150:complications / Q000382:microbiology; D050356:Lipid Metabolism; D024821:Metabolic Syndrome / Q000150:complications; D008727:Methotrexate / Q000009:adverse effects; D065626:Non-alcoholic Fatty Liver Disease; D009784:Occupational Diseases / Q000139:chemically induced; D010480:Perhexiline / Q000009:adverse effects
chemical_list: D044966:Anti-Retroviral Agents; D005938:Glucocorticoids; D010480:Perhexiline; D000638:Amiodarone; D008727:Methotrexate